Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: complement-mediated disorders therapeutics - Alexion AstraZeneca Rare Disease

Next Previous
X
Search
Drug Profile

Research programme: complement-mediated disorders therapeutics - Alexion AstraZeneca Rare Disease

Alternative Names: mAb 171; TA 106; TT 31; TT 32; TT 33

Latest Information Update: 29 Jul 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taligen Therapeutics
  • Developer Alexion AstraZeneca Rare Disease; Alexion Pharmaceuticals
  • Class Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Complement system protein inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Age-related macular degeneration; Asthma; Transplant rejection

Most Recent Events

  • 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (Intraocular, Injection)
  • 01 Feb 2011 Taligen Therapeutics has been acquired and merged into Alexion Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top